You searched for Health Policy and Regulation

We found for

Insight
October 2022

The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics

Insight
June 2022

The Benefits of Early Engagement with Payers and Patient Representatives: The Case Study of a MoCA Pilot Project on ANCA-associated Vasculitis

Krankenschwestern mit Arzt, Generative KI

Insight
May 2022

Ignoring the needs of our future workforce could have disastrous consequences for the UK NHS and its patients.

Insight
February 2022

How Does Pharmaceutical Spending Drive Innovation in Europe?

Insight
December 2021

OHE Critique of CBO’S Pharmaceutical Investment Model Provides Warning for Policymakers on Reliability of Estimates

Insight
September 2021

Does the New CBO Report Change Anything?

Insight
September 2021

Due to the Unprecedented Nature of H.R. 3, the CBO Analysis is Unreliable and Can’t Inform Policymaking

Insight
September 2021

CBO Doesn’t Capture The Real Impact of H.R. 3 on Innovation

Insight
September 2021

The CBO Doesn’t Understand Investors

Insight
September 2021

H.R. 3 is the Wrong Policy for the Wrong Problem

Insight
September 2021

OHE is Launching a New Series to Explore the Latest Attempts to Reduce the Cost of US Healthcare

Insight
June 2021

Towards a New Understanding of Unmet Medical Need

Insight
June 2021

Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?

Insight
March 2021

Does Government Funding Increase Public Sector Development of New Medicines?

News & Insights

Latest Research & Publications

All Publications

We found for

Filter results by

The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics

The Benefits of Early Engagement with Payers and Patient Representatives: The Case Study of a MoCA Pilot Project on ANCA-associated Vasculitis

Ignoring the needs of our future workforce could have disastrous consequences for the UK NHS and its patients.

How Does Pharmaceutical Spending Drive Innovation in Europe?

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

OHE Critique of CBO’S Pharmaceutical Investment Model Provides Warning for Policymakers on Reliability of Estimates

Does the New CBO Report Change Anything?

Due to the Unprecedented Nature of H.R. 3, the CBO Analysis is Unreliable and Can’t Inform Policymaking

CBO Doesn’t Capture The Real Impact of H.R. 3 on Innovation

The CBO Doesn’t Understand Investors

H.R. 3 is the Wrong Policy for the Wrong Problem

OHE is Launching a New Series to Explore the Latest Attempts to Reduce the Cost of US Healthcare

Towards a New Understanding of Unmet Medical Need

Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?

Does Government Funding Increase Public Sector Development of New Medicines?

It Takes Two to Tango: When do Conditional Reimbursement Risk-Sharing Schemes Work for Both Parties?